Shukra Pharmaceuticals Ltd
Incorporated in 1993, Shukra Pharmaceuticals Ltd manufactures and markets pharmaceutical products, and does laboratory testing[1]
- Market Cap ₹ 357 Cr.
- Current Price ₹ 327
- High / Low ₹ 388 / 44.6
- Stock P/E 19.3
- Book Value ₹ 40.8
- Dividend Yield 0.15 %
- ROCE 18.8 %
- ROE 21.2 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company is expected to give good quarter
- Company has delivered good profit growth of 52.8% CAGR over last 5 years
- Company's working capital requirements have reduced from 130 days to 49.0 days
Cons
- Stock is trading at 8.00 times its book value
- Company has a low return on equity of 10.1% over last 3 years.
- Company has high debtors of 187 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
7 | 5 | 4 | 3 | 5 | 5 | 5 | 6 | 12 | 11 | 20 | 59 | 110 | |
6 | 5 | 5 | 3 | 4 | 4 | 4 | 4 | 10 | 10 | 18 | 53 | 91 | |
Operating Profit | 0 | 0 | -0 | -0 | 1 | 1 | 2 | 2 | 2 | 1 | 3 | 5 | 19 |
OPM % | 4% | 9% | -2% | -10% | 24% | 28% | 30% | 29% | 13% | 13% | 14% | 9% | 17% |
2 | -3 | 0 | 1 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | |
Interest | 0 | 0 | 0 | -0 | -0 | 0 | 0 | -0 | -0 | 0 | 0 | 0 | 0 |
Depreciation | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 2 | 2 |
Profit before tax | 2 | -3 | -1 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 4 | 19 |
Tax % | 54% | -0% | -9% | 52% | 66% | 52% | 45% | 37% | 82% | -90% | 26% | 1% | |
1 | -3 | -1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 4 | 19 | |
EPS in Rs | 0.11 | -0.35 | -0.69 | 0.12 | 0.11 | 0.45 | 0.48 | 0.42 | 0.04 | 0.17 | 0.68 | 4.01 | 17.06 |
Dividend Payout % | -0% | -0% | -0% | -0% | -0% | 16% | 15% | 17% | -0% | -0% | 10% | 4% |
Compounded Sales Growth | |
---|---|
10 Years: | 28% |
5 Years: | 62% |
3 Years: | 71% |
TTM: | 411% |
Compounded Profit Growth | |
---|---|
10 Years: | 36% |
5 Years: | 53% |
3 Years: | 504% |
TTM: | 1600% |
Stock Price CAGR | |
---|---|
10 Years: | 99% |
5 Years: | 112% |
3 Years: | 227% |
1 Year: | 561% |
Return on Equity | |
---|---|
10 Years: | 4% |
5 Years: | 7% |
3 Years: | 10% |
Last Year: | 21% |
Balance Sheet
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 9 | 10 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 4 | 11 |
Reserves | -8 | -11 | 12 | 12 | 13 | 13 | 13 | 14 | 14 | 14 | 15 | 21 | 33 |
10 | 10 | 0 | 1 | 0 | 0 | 4 | 6 | 8 | 10 | 3 | 5 | 2 | |
4 | 4 | 4 | 3 | 3 | 4 | 6 | 7 | 10 | 10 | 15 | 45 | 28 | |
Total Liabilities | 16 | 14 | 18 | 18 | 17 | 19 | 24 | 28 | 34 | 36 | 35 | 75 | 74 |
2 | 10 | 10 | 10 | 10 | 10 | 14 | 16 | 17 | 18 | 18 | 20 | 20 | |
CWIP | 0 | 0 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | -0 | -0 |
14 | 3 | 7 | 7 | 6 | 7 | 8 | 11 | 14 | 16 | 16 | 53 | 52 | |
Total Assets | 16 | 14 | 18 | 18 | 17 | 19 | 24 | 28 | 34 | 36 | 35 | 75 | 74 |
Cash Flows
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-7 | -12 | -3 | -2 | 3 | -0 | 1 | 0 | 1 | 1 | 8 | 3 | |
2 | 2 | -10 | 1 | -0 | -1 | -5 | -2 | -3 | -2 | -2 | -4 | |
5 | 5 | -18 | 1 | -1 | -0 | 3 | 2 | 2 | 2 | -7 | 5 | |
Net Cash Flow | -0 | -5 | -31 | 0 | 1 | -1 | -0 | 0 | -0 | 0 | -0 | 4 |
Ratios
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 231 | 92 | 45 | 73 | 71 | 175 | 200 | 345 | 245 | 318 | 132 | 187 |
Inventory Days | 72 | 145 | 134 | 554 | 92 | 112 | 53 | 100 | 169 | 221 | 139 | 25 |
Days Payable | 94 | 173 | 209 | 291 | 108 | 400 | 734 | 1,161 | 786 | 702 | 303 | 276 |
Cash Conversion Cycle | 209 | 64 | -30 | 335 | 54 | -112 | -480 | -717 | -372 | -163 | -32 | -63 |
Working Capital Days | 640 | 111 | 368 | 758 | 258 | 344 | 379 | 440 | 226 | 278 | 61 | 49 |
ROCE % | -2% | -2% | -6% | -1% | 6% | 7% | 6% | 4% | 0% | 1% | 6% | 19% |
Documents
Announcements
- Closure of Trading Window 1h
- Outcome Of Meeting Of Independent Directors Of The Company. 1h
- Intimation Of The Independent Directors Meeting To Be Held On 28Th March, 2024 16 Mar
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
5 Mar - Company has published Notice of Postal ballot in Newspaper.
- Shareholder Meeting / Postal Ballot-Notice of Postal Ballot 4 Mar
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Business Overview:[1][2]
SPL is a is WHO-GMP certified integrated manufacturer of formulations like tablet, capsules and small volume parenteral. It has assisted in the development and manufacture
of a variety of drugs and dosage forms and potency variations for many pharmaceutical companies